

AVAILABLE DOSING FOR GLATOPA: 3-times-a-week 40 mg/mL and once-daily 20 mg/mL¹

Real-world experience. Free patient support. Go Glatopa®.

Glatopa is the lowest-priced glatiramer acetate injection in the US and the #1 prescribed generic glatiramer acetate (20 mg/mL)^{2,3}



~29% of total glatiramer acetate 20 mg/mL prescriptions are for Glatopa 20 mg/mL^{4*}



96% of neurologists surveyed who prescribe Glatopa 20 mg/mL reported being satisfied with Glatopa overall^{5†}



97% of patients surveyed reported being satisfied with their GlatopaCare® experience^{6‡}

Glatopa has treated more than **26,000 patients** since launch in June 2015.⁷

*Adapted from IMS NPA Monthly, Total Glatopa Prescriptions and Sandoz Inc. sales data for Kaiser and the VA. January 2019.

†Independent market research. Neurologists were moderately or extremely satisfied based on a 1–10 scale where 1=not at all satisfied and 10=extremely satisfied, with moderately satisfied scored as 4–7 and extremely satisfied scored as 8–10. Scores were gathered in an online survey of 50 respondents from October to December 2016.⁵

‡Based on a survey conducted August 16–25, 2016, of 151 patients taking Glatopa 20 mg/mL and enrolled in GlatopaCare, using a scale where 1=not at all satisfied and 7=extremely satisfied; 142 patients who answered the survey, or 97%, provided a score of ≥3.⁶

In addition to therapeutic equivalence, Glatopa offers your patients the quality and services you expect with a brand name

	Glatopa (glatiramer acetate injection)	Mylan (glatiramer acetate injection)
Therapeutically equivalent to Copaxone® (glatiramer acetate injection) ⁸	✓	✓
Device does not require a separate Rx⁹	✓	✗
Manufactured in the United States¹⁰⁻¹²	✓	✗
Real-world experience (over 5 years) - 20 mg/mL⁷	✓	✗
Patient starter kit	✓	✗

Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd.

Indication

Glatopa® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Glatopa® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of glatiramer acetate injection 20 mg/mL patients vs 4% of those on placebo, and approximately 2% of glatiramer acetate injection 40 mg/mL patients vs none on placebo experienced a constellation of symptoms that may occur immediately (within seconds to minutes, with the majority of symptoms observed within 1 hour) after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there

have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of glatiramer acetate injection 20 mg/mL patients vs 6% of placebo patients, and approximately 2% of glatiramer acetate injection 40 mg/mL patients vs 1% on placebo. While some episodes of chest pain occurred in the context of the immediate post-injection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various time after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Please see additional Important Safety Information on back and accompanying full Prescribing Information.

Glatopa®
(glatiramer acetate injection)
20mg/mL • 40mg/mL

The Glatopa Patient Starter Kit makes getting started with Glatopa easy

The Glatopa Patient Starter Kit contains everything your patients need to start injecting daily:

- **Sharps container:** Allows for safe and convenient disposal of used needles
- **Cooler bag:** Keeps Glatopa cool while away from home
- **Patient manual:** A patient reference guide to starting Glatopa
- **Injection preparation mat:** Assists patients with injection preparation



Encourage your patients to enroll in GlatopaCare® today and receive a free Patient Starter Kit. Patients can enroll by calling **1.855.GLATOPA (1.855.452.8672)** or by visiting **www.glatopa.com/register**

Glatopa Co-Pay Program Eligibility

The Glatopa Co-Pay Program provides up to \$9000 in annual co-pay support for Glatopa prescriptions. This program is not health insurance. This program is for insured patients only; uninsured cash-paying patients are not eligible. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Card may not be combined with any other rebate, coupon, or offer. Card has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

References: **1.** Glatopa Prescribing Information. Sandoz Inc. January 2020. **2.** Data on file. IMS Health. Sandoz Inc. February 2018. **3.** Data on file. Analy\$ource. Sandoz Inc. March 2020. **4.** Data on file. Glatopa Sales Data. Sandoz Inc. January 2019. **5.** Spherix Global Insights. RealTime Dynamix: Multiple Sclerosis. December 2016. **6.** Data on file. RxCrossroads GlatopaCare Survey. Sandoz Inc. August 2016. **7.** Data on file. IMS SMART Patient Insights. Sandoz Inc. March 2020. **8.** US Department of Health and Human Services. Orange Book: Approved drug products with therapeutic equivalence evaluations. <https://www.fda.gov/media/71474/download>. Accessed March 27, 2020. **9.** Glatopa Prescribing Information. Sandoz Inc. January 2018. **10.** Glatopa™ (glatiramer acetate injection) approved for the long-term treatment of relapsing forms of MS. Multiple Sclerosis Association of America website. <https://mymsaa.org/news/glatopa-approved>. Published April 17, 2015. Accessed March 11, 2020. **11.** Glatiramer Acetate Injection 20 mg/mL Prescribing Information. Mylan Pharmaceuticals Inc. August 2019. **12.** Glatiramer Acetate Injection 40 mg/mL Prescribing Information. Mylan Pharmaceuticals Inc. August 2019.

Important Safety Information (cont'd)

Because glatiramer acetate can modify immune response, it may interfere with immune functions. For example, treatment with glatiramer acetate may interfere with recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. There is no evidence that glatiramer acetate does this, but there has not been a systematic evaluation of this risk.

The most common adverse reactions with glatiramer acetate injection 20 mg/mL vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%). The most common adverse reactions with glatiramer acetate injection 40 mg/mL vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of glatiramer acetate injection. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with glatiramer acetate than placebo.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information on cover and accompanying full Prescribing Information.

SANDOZ A Novartis Division

Glatopa and GlatopaCare are registered trademarks of Novartis AG.
© 2020 Sandoz, a Novartis Division. 100 College Road West, Princeton, NJ 08540.
All Rights Reserved. S-GLA-1390168 05/2020

Glatopa[®]
(glatiramer acetate injection)
20mg/mL • 40mg/mL